Product Description
Mechanisms of Action: RR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: Eastern America
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Brain Cancer
Phase 2: Non-Small-Cell Lung Cancer|Lymphoma, Non-Hodgkin|Renal Cell Carcinoma|Melanoma|Lymphoma, B-Cell|Breast Cancer|Brain Cancer|Glioblastoma|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Gliosarcoma|Glioma|Brain Stem Cancer|Adenocarcinoma|Multiple Myeloma
Phase 1: Glioma|Prostate Cancer|Breast Cancer|Ovarian Cancer|Astrocytoma|Glioblastoma|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Bronchogenic Carcinoma|Squamous Cell Carcinoma|Oropharyngeal Cancer|Oligodendroglioma|Head and Neck Cancer|Hypopharyngeal Cancer|Myelodysplastic-Myeloproliferative Diseases|Laryngeal Cancer|Plasmacytoma|Leukemia, Plasma Cell|Colorectal Cancer|Multiple Myeloma|Prostatic Diseases|Lung Cancer|Intestinal Cancer|Breast Diseases|Intestinal Diseases|Rectal Diseases|Myeloproliferative Disorders|Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01562223 |
A6701QIBA | N/A |
Unknown status |
Prostate Cancer |
2022-12-01 |
2023-08-03 |
Primary Endpoints|Treatments|Trial Status |
|
NCT00087191 |
NCI-2012-02607 | N/A |
Terminated |
Malignant Carcinoid Syndrome|Gastrointestinal Stromal Tumors|Adenocarcinoma|Bile Duct Cancer|Gallbladder Cancer|Pancreatic Cancer|Peritoneal Cancer|Gastrointestinal Cancer|Lymphoma|Cholangiocarcinoma|Uterine Cancer|Embryonal Carcinoma|Germinoma|Leiomyosarcoma|Colorectal Cancer|Non-Small-Cell Lung Cancer|Fallopian Tube Cancer|Carcinoid Tumor|Appendiceal Cancer|Liver Cancer|Soft Tissue Cancer|Ovarian Cancer |
2006-01-01 |
2019-03-22 |
Treatments |
|
NCT00003909 |
NCI-2012-01845 | P1 |
Completed |
Glioma |
2007-03-01 |
2019-03-21 |
Treatments |
|
NCT00036790 |
CDR0000069322 | P1 |
Completed |
Head and Neck Cancer|Plasmacytoma|Multiple Myeloma|Prostate Cancer|Myelodysplastic-Myeloproliferative Diseases|Breast Cancer|Prostatic Diseases|Rectal Diseases|Intestinal Diseases|Myeloproliferative Disorders|Lymphoma|Breast Diseases|Leukemia, Plasma Cell|Colorectal Cancer|Lung Cancer|Intestinal Cancer |
2005-10-01 |
2024-11-27 |
Treatments |
|
NCT00080041 |
PCYC-0214 | P1 |
Completed |
Prostate Cancer|Breast Cancer|Ovarian Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00120939 |
PCYC-0212 | P1 |
Completed |
Breast Cancer|Ovarian Cancer|Gastrointestinal Cancer|Prostate Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00080054 |
PCYC-0218 | P1 |
Completed |
Astrocytoma|Glioblastoma|Oligodendroglioma |
None |
2019-03-21 |
Treatments |
|
NCT00102505 |
PCYC-0220 | P1 |
Completed |
Non-Small-Cell Lung Cancer|Bronchogenic Carcinoma |
None |
2019-03-21 |
Treatments |
|
NCT00080028 |
PCYC-0210 | P1 |
Terminated |
Squamous Cell Carcinoma|Oropharyngeal Cancer|Head and Neck Cancer|Hypopharyngeal Cancer|Laryngeal Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00305864 |
NCI-2009-01092 | P2 |
Completed |
Gliosarcoma|Glioblastoma |
2011-02-16 |
2019-03-21 |
||
NCT00387790 |
NCI-2012-01829 | P2 |
Completed |
Glioma |
2010-04-01 |
2019-03-22 |
Treatments |
|
NCT00100711 |
PCYC-0222 | P2 |
Terminated |
Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2010-02-01 |
2019-03-21 |
Treatments |
|
NCT00373204 |
PCYC-0229 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2008-02-01 |
2019-03-21 |
Treatments |
|
NCT00365183 |
PCYC-0228 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2008-01-01 |
2019-03-21 |
Treatments |
|
NCT00129844 |
PCYC-0227 | P2 |
Completed |
Non-Small-Cell Lung Cancer|Adenocarcinoma |
2007-06-01 |
2019-03-21 |
Treatments |
|
NCT00290004 |
PCYC-0223 | P2 |
Completed |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Lymphoma, B-Cell |
2007-02-01 |
2019-03-21 |
Treatments |
|
NCT00089284 |
NU 02H8 | P2 |
Terminated |
Lymphoma, Non-Hodgkin |
2007-01-01 |
2019-08-18 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT00022256 |
MSKCC-01051 | P2 |
Completed |
Glioblastoma|Brain Stem Cancer |
2003-04-01 |
2019-03-21 |
||
NCT00134186 |
PCYC-0219 | P2 |
Completed |
Renal Cell Carcinoma |
None |
2019-03-21 |
Treatments |
|
NCT00121420 |
PCYC-0224 | P2 |
Terminated |
Melanoma|Breast Cancer|Brain Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00086034 |
PCYC-0221 | P2 |
Completed |
Lymphoma, Non-Hodgkin |
None |
2019-03-21 |
Treatments |
|
NCT00076401 |
PCYC-0216 | P2 |
Terminated |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
None |
2019-03-21 |
||
NCT00096837 |
PCYC-0215 | P2 |
Completed |
Multiple Myeloma |
None |
2019-03-21 |
Treatments |
|
NCT00054795 |
SMART | P3 |
Completed |
Non-Small-Cell Lung Cancer|Brain Cancer |
None |
2019-03-21 |
Treatments |